Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

AbbVie Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Turnover Ratios
Inventory turnover 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96 5.58 5.76 5.45 5.40 4.65
Receivables turnover 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29 5.63 5.94 5.42 5.24 5.19
Working capital turnover 130.12
Average No. Days
Average inventory processing period 107 98 90 89 75 75 73 77 85 81 75 66 73 74 65 63 67 68 79
Add: Average receivable collection period 79 79 71 75 78 80 75 76 75 74 71 68 72 69 65 61 67 70 70
Operating cycle 186 177 161 164 153 155 148 153 160 155 146 134 145 143 130 124 134 138 149

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


Inventory Turnover
The inventory turnover ratio demonstrates a declining trend over the observed periods. It began around 4.65 in early 2020 and increased slightly to a peak of 5.76 by the end of 2020. However, starting from 2021, the ratio gradually decreased, reaching approximately 3.42 by the first quarter of 2025. This indicates a slowdown in the rate at which inventory is sold and replaced over time.
Receivables Turnover
The receivables turnover ratio remained relatively stable with minor fluctuations. It oscillated between roughly 5.19 and 5.94 during 2020 and 2021 before gradually declining to a range of about 4.6 to 4.87 towards the first half of 2025. This suggests a slight decrease in the efficiency of collecting receivables over the periods.
Working Capital Turnover
Data for working capital turnover is only available for one period, recorded at 130.12. Due to lack of further data points, no trend analysis can be performed for this metric.
Average Inventory Processing Period
The average inventory processing period, expressed in days, exhibits an overall increasing trend. Starting from 79 days in early 2020, it declined to a low of 63 days near the end of 2020, indicating quicker inventory processing at that time. However, from 2021 onwards, the period progressively lengthened, reaching 107 days by the end of the first quarter of 2025, pointing to slower inventory turnover over time.
Average Receivable Collection Period
The average receivable collection period remained fairly steady initially, fluctuating around 60 to 70 days in 2020 and 2021. Subsequently, the period tended to increase, reaching approximately 79 days by early 2025. This indicates a gradual extension in the time taken to collect receivables over the analyzed timeframe.
Operating Cycle
The operating cycle, which combines inventory processing and receivables collection periods, exhibited a decreasing trend in 2020, dropping from 149 to 124 days. Following this, the cycle gradually lengthened, moving from 130 days in early 2021 to 186 days by the first quarter of 2025. This suggests increasing total time to turn inventory into cash, reflecting slower operational efficiency in the company's working capital management over time.

Turnover Ratios


Average No. Days


Inventory Turnover

AbbVie Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Cost of products sold 4,346 4,002 4,396 4,212 4,202 4,094 5,704 6,485 4,240 3,986 4,170 5,022 4,170 4,052 4,320 4,390 4,523 4,213 4,684 5,050 3,711 1,942
Inventories 4,960 4,526 4,181 4,450 4,218 4,245 4,099 3,981 4,055 3,833 3,579 3,172 3,396 3,483 3,128 3,094 3,386 3,272 3,310 3,474 4,059 1,844
Short-term Activity Ratio
Inventory turnover1 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96 5.58 5.76 5.45 5.40 4.65
Benchmarks
Inventory Turnover, Competitors2
Amgen Inc. 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48 1.58 1.53 1.53 1.53 1.58
Bristol-Myers Squibb Co. 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55 4.74 4.85 5.01 5.61 5.68
Danaher Corp. 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87 4.16 4.06 4.28 4.34 4.28
Eli Lilly & Co. 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93 1.88 1.79 1.80 1.68 1.38
Gilead Sciences Inc. 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50 4.08 3.21 2.99 2.79 2.72
Johnson & Johnson 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04
Merck & Co. Inc. 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74 2.29 2.73 2.79 2.40 2.45
Pfizer Inc. 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67 3.40 2.78 1.80 1.28 1.08
Regeneron Pharmaceuticals Inc. 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27 1.25 0.88 0.82 0.56 0.58
Thermo Fisher Scientific Inc. 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87 3.88 3.90 4.03 4.01 4.02
Vertex Pharmaceuticals Inc. 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83 2.56 2.58 2.52 2.56 2.62

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Inventory turnover = (Cost of products soldQ2 2025 + Cost of products soldQ1 2025 + Cost of products soldQ4 2024 + Cost of products soldQ3 2024) ÷ Inventories
= (4,346 + 4,002 + 4,396 + 4,212) ÷ 4,960 = 3.42

2 Click competitor name to see calculations.


The cost of products sold exhibits noticeable fluctuations over the observed periods, with peaks and troughs that suggest variability in production or sales volume. Initially, there is a sharp increase from March 2020 to September 2020, reaching a high point above 5,000 million USD. This is followed by a decline toward early 2021. Mid-2023 and late 2023 mark significant spikes, with the cost peaking again near or above previous high levels. The most recent data points indicate a downward adjustment, though values remain elevated compared to early 2020 levels.

Inventories show an overall increasing trend throughout the periods, albeit with some oscillations. Starting below 2,000 million USD in early 2020, inventories rose markedly in mid-2020, subsequently decreasing in the following quarters but remaining consistently higher than the initial values. From late 2022 onward, inventory levels demonstrate a steady upward movement, reaching their highest values in the final quarters, surpassing 4,500 million USD. This suggests growing stock accumulation or slower turnover in recent periods.

The inventory turnover ratio, available from December 2020 onward, reveals a generally declining trend. It began at approximately 4.65 and increased modestly to peak near 5.76 in early 2021, indicating a period when inventories were converted to sales more rapidly. Following this peak, turnover ratios decline progressively over the subsequent periods, falling below 4.0 in the last few quarters observed. The downward trend in turnover implies a decreasing efficiency in managing or selling inventory, which could be associated with the increasing inventory levels documented.

Cost of products sold
Displays significant variation with notable peaks around September 2020 and late 2023, and a general elevation compared to early 2020 levels.
Inventories
Incremental increase over time with highest values recorded in late 2024 and early 2025, indicating accumulation of stock.
Inventory turnover ratio
Peaked in early 2021 but shows a gradual decline afterwards, suggesting reduced inventory movement efficiency.

Receivables Turnover

AbbVie Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Net revenues 15,423 13,343 15,102 14,460 14,462 12,310 14,301 13,927 13,865 12,225 15,121 14,812 14,583 13,538 14,886 14,342 13,959 13,010 13,858 12,902 10,425 8,619
Accounts receivable, net 12,637 12,477 10,919 11,472 11,724 11,949 11,155 11,412 11,491 11,473 11,254 10,743 11,237 10,733 9,977 9,281 9,914 9,588 8,822 8,416 8,354 6,362
Short-term Activity Ratio
Receivables turnover1 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29 5.63 5.94 5.42 5.24 5.19
Benchmarks
Receivables Turnover, Competitors2
Amgen Inc. 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81 4.96 5.11 5.39 5.41 5.36
Danaher Corp. 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87 6.36 6.69 6.51 6.28 5.51
Eli Lilly & Co. 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64 4.24 4.69 4.58 4.56 4.18
Gilead Sciences Inc. 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18 6.01 5.95 6.34 6.43 4.98
Johnson & Johnson 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08
Merck & Co. Inc. 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49 5.28 5.56 6.00 5.65 6.11
Pfizer Inc. 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99 7.08 5.81 5.23 4.70 5.28
Regeneron Pharmaceuticals Inc. 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41 2.66 2.48 1.77 2.20 2.07
Thermo Fisher Scientific Inc. 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21 4.92 7.03 6.99 6.46 5.61
Vertex Pharmaceuticals Inc. 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15 6.66 6.48 7.19 6.56 7.01

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Receivables turnover = (Net revenuesQ2 2025 + Net revenuesQ1 2025 + Net revenuesQ4 2024 + Net revenuesQ3 2024) ÷ Accounts receivable, net
= (15,423 + 13,343 + 15,102 + 14,460) ÷ 12,637 = 4.62

2 Click competitor name to see calculations.


Net Revenues
The net revenues exhibit a general upward trend with notable seasonal fluctuations across quarters. From March 2020 to December 2020, revenues increased steadily from approximately $8.6 billion to $13.9 billion. This upward momentum continued into 2021, peaking near $14.9 billion in the final quarter. A decline appears at the start of 2023 with revenues declining to approximately $12.2 billion in Q1 2023, followed by recovery in subsequent quarters reaching about $15.4 billion by mid-2025. This cyclical pattern suggests potential industry seasonality or external factors influencing quarterly performance. Overall, revenue growth appears positive over the five-year span despite intermittent dips.
Accounts Receivable, Net
Accounts receivable demonstrate a predominantly increasing trajectory over the period. Beginning at approximately $6.4 billion in Q1 2020, the balance rose steadily, crossing $11 billion in early 2022, and continuing to progress beyond $12 billion into 2025. The growth in receivables generally parallels the growth in net revenues, though receivables appear to accumulate at a higher relative pace during certain quarters, such as in early 2023 and mid-2025. This may indicate extended collection periods or changes in credit terms. Despite the increase, the company maintains a sizeable receivable balance consistent with its expanding revenue base.
Receivables Turnover Ratio
The receivables turnover ratio, available from Q4 2020 onwards, exhibits a declining trend. Initially reported at approximately 5.19, the ratio increased slightly in the following quarters reaching a peak near 5.94 but then commenced a gradual decline to figures around 4.6 to 4.8 by 2024–2025. A lower turnover ratio suggests that it is taking longer for the company to collect receivables relative to sales. This trend, combined with the increasing accounts receivable balances, may indicate potential easing of payment collection efficiency or strategic extension of credit to customers.
Overall Insights
The data indicates strong revenue growth accompanied by a parallel increase in receivables. However, the declining receivables turnover ratio signals a potential slowing in cash collection efficiency. While the company is expanding its sales, receivables management might require attention to mitigate liquidity risks. The seasonal and cyclical fluctuations in revenue also suggest the necessity for ongoing monitoring of market or operational factors influencing quarterly results. The interplay between increasing revenues, rising receivables, and decreasing turnover ratio warrants careful analysis to maintain financial stability.

Working Capital Turnover

AbbVie Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Current assets 29,261 27,675 25,582 27,785 33,816 38,871 33,002 33,224 28,852 26,488 28,463 30,364 29,100 26,509 27,928 28,957 25,999 26,569 24,173 23,009 21,256 51,758
Less: Current liabilities 39,767 36,403 38,749 43,062 41,915 41,522 37,841 34,773 32,239 27,590 29,538 32,712 34,473 32,521 35,194 28,533 28,684 31,951 28,661 24,181 24,646 16,471
Working capital (10,506) (8,728) (13,167) (15,277) (8,099) (2,651) (4,839) (1,549) (3,387) (1,102) (1,075) (2,348) (5,373) (6,012) (7,266) 424 (2,685) (5,382) (4,488) (1,172) (3,390) 35,287
 
Net revenues 15,423 13,343 15,102 14,460 14,462 12,310 14,301 13,927 13,865 12,225 15,121 14,812 14,583 13,538 14,886 14,342 13,959 13,010 13,858 12,902 10,425 8,619
Short-term Activity Ratio
Working capital turnover1 130.12
Benchmarks
Working Capital Turnover, Competitors2
Amgen Inc. 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34 3.37 2.55 5.35 2.84 2.55
Bristol-Myers Squibb Co. 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24 3.95 4.43 4.24 4.25 3.72
Danaher Corp. 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91 8.40 7.98 3.12 3.45 3.48
Eli Lilly & Co. 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19 8.33 6.73 12.14 5.21 4.93
Gilead Sciences Inc. 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68 8.54 7.25 7.09 7.06 5.30
Johnson & Johnson 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57 5.95 5.97 5.93 7.26 9.44
Merck & Co. Inc. 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09 7.62 6.51 6.97 84.97 109.83
Pfizer Inc. 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10 4.78 4.29 4.21 3.60 4.58
Regeneron Pharmaceuticals Inc. 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46 1.59 1.35 1.29 1.35 1.20
Thermo Fisher Scientific Inc. 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13 5.87 2.30 3.10 3.36 2.76
Vertex Pharmaceuticals Inc. 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97 1.02 1.03 1.01 0.97 0.99

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Working capital turnover = (Net revenuesQ2 2025 + Net revenuesQ1 2025 + Net revenuesQ4 2024 + Net revenuesQ3 2024) ÷ Working capital
= (15,423 + 13,343 + 15,102 + 14,460) ÷ -10,506 =

2 Click competitor name to see calculations.


Working Capital
Working capital exhibited significant volatility across the reported periods. Initially, there was a strong positive figure reported at the end of the first quarter of 2020, followed by multiple consecutive quarters featuring negative values, indicating potential liquidity challenges during those periods. Despite occasional recoveries where working capital returned to positive or near-neutral territory, the general trend shows a decline in working capital over time, reaching notably negative levels by the latter quarters ending in 2024 and 2025. This fluctuation suggests periodic strains in managing current assets and liabilities effectively.
Net Revenues
Net revenues generally showed a positive growth trajectory with intermittent fluctuations. The figures rose steadily from early 2020 through to late 2021, reflecting consistent revenue growth during this timeframe. However, there was a notable decline in revenue in early 2023, before revenues stabilized and resumed an upward trend in subsequent quarters through 2024 and into early 2025. The periodic decreases in revenue could be interpreted as market or operational challenges which were later mitigated, given the return to growth.
Working Capital Turnover
The working capital turnover ratio was only reported for one quarter, displaying a very high value early in the data set. The absence of further data limits the ability to analyze trends or confirm if turnover ratios sustained similar levels or declined. The single high figure might indicate efficient use of net working capital to generate net revenues during that specific period, but no ongoing pattern can be inferred.

Average Inventory Processing Period

AbbVie Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data
Inventory turnover 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96 5.58 5.76 5.45 5.40 4.65
Short-term Activity Ratio (no. days)
Average inventory processing period1 107 98 90 89 75 75 73 77 85 81 75 66 73 74 65 63 67 68 79
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
Amgen Inc. 194 195 199 209 257 321 411 259 265 279 281 272 260 247 231 239 239 239 231
Bristol-Myers Squibb Co. 70 69 67 102 98 99 91 84 83 93 84 76 79 80 77 75 73 65 64
Danaher Corp. 101 96 88 101 102 98 96 104 102 104 91 96 98 94 88 90 85 84 85
Eli Lilly & Co. 435 379 329 349 316 312 298 261 267 268 237 196 204 189 194 204 203 217 265
Gilead Sciences Inc. 108 103 100 101 110 102 100 105 106 102 97 78 81 81 89 114 122 131 134
Johnson & Johnson 168 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Merck & Co. Inc. 162 150 147 149 153 151 144 139 137 134 124 118 119 133 159 134 131 152 149
Pfizer Inc. 239 229 222 219 178 170 149 138 158 119 95 101 100 99 107 131 203 284 338
Regeneron Pharmaceuticals Inc. 570 582 572 573 562 553 519 508 532 549 562 440 379 287 292 415 445 653 625
Thermo Fisher Scientific Inc. 80 76 72 79 76 74 72 76 79 79 79 85 91 94 94 94 91 91 91
Vertex Pharmaceuticals Inc. 345 320 287 267 238 222 214 213 192 177 156 136 135 129 143 142 145 142 139

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.42 = 107

2 Click competitor name to see calculations.


Inventory Turnover Ratio
The inventory turnover ratio exhibits a fluctuating decline over the observed periods. Beginning at 4.65 in March 2020, it increased moderately to a peak of 5.76 by December 2020. After this peak, the ratio generally trended downward, falling to 3.42 by March 2025. This trend suggests a reduction in the frequency with which inventory is sold and replaced over time, potentially indicating slower inventory movement or increased inventory levels relative to sales.
Average Inventory Processing Period (Days)
The average inventory processing period shows an inverse pattern relative to the turnover ratio, as expected due to their mathematical relationship. Starting at 79 days in March 2020, it decreased to a low of 63 days by December 2020, coinciding with the peak inventory turnover. Following that, the days steadily increased, reaching 107 days by March 2025. This increase indicates that inventory is being held for a longer period before being processed or sold, which may imply slower sales cycles or excess inventory buildup.
Overall Inventory Management Insight
The observed data indicates a deterioration in inventory management efficiency over the period from early 2020 through early 2025. Initially, improvements led to faster inventory turnover and reduced holding periods up to late 2020. However, sustained declines in turnover and corresponding increases in processing days thereafter point to potential challenges in managing inventory levels relative to sales demand. This trend may warrant further investigation into sales performance, supply chain management, or market conditions influencing inventory dynamics.

Average Receivable Collection Period

AbbVie Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data
Receivables turnover 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29 5.63 5.94 5.42 5.24 5.19
Short-term Activity Ratio (no. days)
Average receivable collection period1 79 79 71 75 78 80 75 76 75 74 71 68 72 69 65 61 67 70 70
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
Amgen Inc. 95 91 77 86 86 88 99 88 84 84 82 79 79 76 74 71 68 67 68
Danaher Corp. 54 54 54 54 51 52 60 59 55 53 57 51 54 53 57 55 56 58 66
Eli Lilly & Co. 97 90 89 92 103 80 97 93 93 99 88 84 80 79 86 78 80 80 87
Gilead Sciences Inc. 61 56 56 59 62 62 63 64 57 57 65 59 55 51 61 61 58 57 73
Johnson & Johnson 72 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Merck & Co. Inc. 68 62 58 66 68 68 63 64 69 66 58 59 62 66 69 66 61 65 60
Pfizer Inc. 69 69 66 87 74 72 69 58 48 48 40 59 55 52 52 63 70 78 69
Regeneron Pharmaceuticals Inc. 144 144 160 161 155 146 158 156 148 151 160 148 132 107 137 147 206 166 177
Thermo Fisher Scientific Inc. 73 72 70 71 68 68 70 70 67 66 66 63 66 70 74 52 52 56 65
Vertex Pharmaceuticals Inc. 61 59 53 60 58 64 58 58 60 61 59 58 58 59 55 56 51 56 52

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.62 = 79

2 Click competitor name to see calculations.


Receivables Turnover Ratio
The receivables turnover ratio data begins from March 31, 2021. Initially, the ratio shows an upward trend, rising from 5.19 to a peak of 5.94 by December 31, 2020 (considering available data from March 2021 onwards, this peak occurs likely earlier in that timeline). After this peak, the ratio generally declines, dropping to 4.83 by September 30, 2023. There are minor fluctuations observed thereafter, with the ratio slightly increasing to 4.87 by December 31, 2023, followed by dips and modest recoveries through 2024. Overall, the ratio trends downward from its high point, ending near 4.62 by June 30, 2025.
Average Receivable Collection Period
The average receivable collection period inversely reflects the pattern of the receivables turnover ratio. Starting at 70 days in March and June 2020, the collection period shortens to 61 days by December 31, 2020, indicating more efficient collection during this period. However, following this, there is a trend towards lengthening collection periods, with days increasing to 76 by September 30, 2023, which suggests a decline in collection efficiency. The collection period then stabilizes around the mid-70s to high 70s days range through mid-2025, with a minor improvement to 71 days by March 31, 2025, but rising again to 79 days by June 30, 2025.
Interpretation and Insights
The initial improvement in receivables turnover ratio and reduction in collection days during 2020 indicates enhanced operational efficiency in receivable management. However, the subsequent and persistent decline in turnover ratio coupled with increasing collection days from 2021 onward may reflect challenges in maintaining this efficiency over time. This could be due to several factors, such as lenient credit policies, slower customer payments, or changes in the sales mix. The fluctuations and eventual stabilization in collection days near higher levels highlight a potential area of concern in working capital management, signaling the need for operational focus to improve or maintain receivable collection.

Operating Cycle

AbbVie Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data
Average inventory processing period 107 98 90 89 75 75 73 77 85 81 75 66 73 74 65 63 67 68 79
Average receivable collection period 79 79 71 75 78 80 75 76 75 74 71 68 72 69 65 61 67 70 70
Short-term Activity Ratio
Operating cycle1 186 177 161 164 153 155 148 153 160 155 146 134 145 143 130 124 134 138 149
Benchmarks
Operating Cycle, Competitors2
Amgen Inc. 289 286 276 295 343 409 510 347 349 363 363 351 339 323 305 310 307 306 299
Danaher Corp. 155 150 142 155 153 150 156 163 157 157 148 147 152 147 145 145 141 142 151
Eli Lilly & Co. 532 469 418 441 419 392 395 354 360 367 325 280 284 268 280 282 283 297 352
Gilead Sciences Inc. 169 159 156 160 172 164 163 169 163 159 162 137 136 132 150 175 180 188 207
Johnson & Johnson 240 228 226 236 233 222 218 211 232 220 209 196 198 192 186 188 186 193 180
Merck & Co. Inc. 230 212 205 215 221 219 207 203 206 200 182 177 181 199 228 200 192 217 209
Pfizer Inc. 308 298 288 306 252 242 218 196 206 167 135 160 155 151 159 194 273 362 407
Regeneron Pharmaceuticals Inc. 714 726 732 734 717 699 677 664 680 700 722 588 511 394 429 562 651 819 802
Thermo Fisher Scientific Inc. 153 148 142 150 144 142 142 146 146 145 145 148 157 164 168 146 143 147 156
Vertex Pharmaceuticals Inc. 406 379 340 327 296 286 272 271 252 238 215 194 193 188 198 198 196 198 191

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 107 + 79 = 186

2 Click competitor name to see calculations.


Average inventory processing period
The average inventory processing period shows a general upward trend over the analyzed quarters. Starting from 79 days in the first recorded quarter, it decreases slightly to the mid-60s by the end of 2020 but then progressively rises. Throughout 2022 and 2023, the period fluctuates mostly between the mid-70s and low 80s, before increasing more sharply toward the end of the dataset, reaching 107 days by the last quarter of 2025. This indicates a slowdown in inventory turnover over time, suggesting either longer holding times for inventory or slower sales fulfillment.
Average receivable collection period
The average receivable collection period remains relatively stable with moderate fluctuations around 70 days. Initially, it holds steady at 70 days but dips to a low of 61 days by the end of 2020. Subsequently, the period generally trends upward, peaking at 80 days in mid-2024, before declining slightly to 75-79 days towards the end of the timeframe. This pattern reflects some variability in customer payment behaviors but no drastic changes in credit policy or collections efficiency.
Operating cycle
The operating cycle exhibits an increasing trend over the reported range. It starts from 149 days early in the data and decreases gradually to around 124 days by the end of 2020. Afterward, the cycle lengthens steadily, reaching 186 days by the final quarter of the dataset. This increase corresponds with the combined effect of longer inventory processing times and slightly extended receivable collection periods. The elongation of the operating cycle may point to a lengthening of the cash conversion cycle, possibly impacting working capital requirements and liquidity.